Search for: "Boehringer Ingelheim Pharmaceuticals"
Results 61 - 80
of 252
Sorted by Relevance
|
Sort by Date
25 Nov 2013, 1:44 pm
"Old" Warfarin Treatment (Posted by Tom Lamb at DrugInjuryWatch.com) A report published online in November 2013 by the medical journal JAMA: Internal Medicine, "A comparison of results of the US Food and Drug Administration's Mini-Sentinel Program with randomized clinical trials: The case of gastrointestinal tract bleeding with dabigatran", raises more drug-safety issues for the still relatively new blood thinner Pradaxa, from Boehringer Ingelheim Pharmaceuticals. [read post]
19 Dec 2010, 9:44 am
--Naik v Boehringer Ingelheim Pharm, Inc., 7thCir, November 22, 2010, No. 09-2960: Summary judgment upheld for employer after 53-year-old former pharmaceutical sales rep failed to show that termination based on falsification of call records, was pretext for age and national origin (Indian) discrimination in violation of the Age Discrimination in Employment Act (ADEA) and Title VII.The employer's legitimate non-discriminatory reason (LNDR) was pretty damning against… [read post]
30 Apr 2012, 9:36 pm
The estate of a woman who bled to death is suing pharmaceutical company Boehringer Ingelheim for her wrongful death. [read post]
28 Jul 2011, 11:19 am
Boehringer Ingelheim Pharmaceuticals, No. 10-3129, slip op. (8th Cir. [read post]
6 Feb 2014, 6:41 am
According to newly unsealed legal documents, Boehringer Ingelheim, the manufacturer of the blood-thinning drug Pradaxa were anxious that an internal research paper would damage drug sales and they suggested it should be suppressed. [read post]
17 Sep 2016, 7:08 am
Specifically, the decision is being lauded by Boehringer Ingelheim, the makers of Pradaxa, according to a recent news feature from FiercePharma. [read post]
17 Sep 2016, 7:08 am
Specifically, the decision is being lauded by Boehringer Ingelheim, the makers of Pradaxa, according to a recent news feature from FiercePharma. [read post]
4 Nov 2015, 9:34 am
According to a recent news article from the Washington Post, a federal watch group reports the United States Food and Drug Administration (FDA) exercised “lax” judgment and made “questionable” decisions to be accommodating to the pharmaceutical maker Boehringer Ingelheim when reviewing its application for the anticlotting medication known as Pradaxa. [read post]
1 Mar 2013, 9:53 pm
As reported, Bristol-Myers Squibb, Roche and Boehringer-Ingelheim have plans to join the pool. [read post]
20 Aug 2012, 11:15 am
Since coming on the market in October 2010 the FDA has received numerous Adverse Event Reports involving: • Serious bleeding side effects • Hemorrhages such as hemorrhagic stroke In addition, some medical studies have associated Pradaxa with an increased risk: • Heart attack • Myocardial infarction (MI)• Acute coronary syndrome (ACS) Due to these serious side effects, a growing number of personal injury and wrongful death Pradaxa lawsuits have been filed against… [read post]
21 Mar 2017, 12:23 pm
Boehringer Ingelheim Pharmaceuticals, Inc. markets this prescription anticoagulant drug. [read post]
12 Apr 2017, 2:22 pm
One hopes that Boehringer Ingelheim Pharmaceuticals (Pradaxa) or Janssen Pharmaceuticals (Xarelto) or one of the other responsible drug companies have such a drug-safety study currently underway or planned to begin soon. [read post]
26 Jul 2023, 1:53 am
In an invalidity lawsuit filed by the Brazilian affiliate of Sun Pharma against Boehringer Ingelheim, Federal Judge Carvalho, sitting at the 9th Federal District Court in Rio de Janeiro, has granted a preliminary injunction ordering the Brazilian Patent and Trademark Office (BRPTO) to annotate that a second medical use patent (covering Ofev) doesn’t prevent the manufacturing and/or selling of generic or brand-generic nintedanib-based drugs for other uses. [read post]
17 Nov 2014, 1:20 pm
The first such new blood thinner released was Pradaxa (dabigatran), a direct thrombin inhibitor by Boehringer Ingelheim. [read post]
27 Jun 2018, 1:16 am
The Court concluded that their actions therefore would not amount to repackaging as set out in Boehringer Ingelheim. [read post]
27 Jun 2018, 1:16 am
The Court concluded that their actions therefore would not amount to repackaging as set out in Boehringer Ingelheim. [read post]
13 Nov 2019, 9:15 am
Boehringer Ingelheim International GMBH, IPR2016-01563, Paper 16 (Feb. 3, 2017), that a relied-upon Glucophage label had no source identifying information or indicia of when it became publicly available and the declaration attesting to its publication was not based on personal knowledge, but was merely conclusory. [read post]
16 Jun 2011, 10:59 am
This news service has previously reported that the Amylin-Lilly partnership may be at risk due to Lilly’s collaboration with Boehringer Ingelheim. [read post]
18 Jul 2012, 3:58 pm
So even though Pradaxa has been associated with problems like pulmonary embolism and other heart issues, it remains a blockbuster product for Boehringer Ingelheim. [read post]
11 Jan 2018, 12:30 pm
Boehringer Ingelheim Pharmaceuticals, Inc. is the drug company responsible for OFEV in the US. [read post]
